February 24, 2020—On February 13, 2020, the U.S. Food and Drug Administration (FDA) issued a safety communication to healthcare professionals about Belviq, Belviq XR (lorcaserin). The FDA requested that the manufacturer, Eisai Inc., voluntarily recall its weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer.
The drug manufacturer has submitted a request to voluntarily withdraw the drug.
The guidelines suggested here are not rules, do not constitute legal advice, and do not ensure a successful outcome. The ultimate decision regarding the appropriateness of any treatment must be made by each healthcare provider considering the circumstances of the individual situation and in accordance with the laws of the jurisdiction in which the care is rendered.